当前位置: X-MOL 学术Heart › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Point: patients with native aortic regurgitation can be treated with transcatheter aortic valve implantation
Heart ( IF 5.7 ) Pub Date : 2021-12-01 , DOI: 10.1136/heartjnl-2021-319179
Sahoor A Khan 1 , Suzanne J Baron 2
Affiliation  

Approximately 2% of people between the ages of 70 and 83 suffer from moderate or greater aortic regurgitation (AR) in the United States. Left untreated, this disease is progressive and fatal; however, up to 8% of patients with AR, who meet the criteria for surgical intervention, do not receive treatment. As such, there is a pressing need to address the lack of treatment options for the thousands of patients with AR who meet a class I indication for aortic valve replacement but who still do not receive surgery. The advent of transcatheter aortic valve implantation (TAVI) has significantly altered the paradigm of treatment for valvular heart disease and is now a well-established therapeutic option for patients with severe aortic stenosis. While transcatheter devices dedicated for the treatment of AR are under investigation, they are not commercially available at this time. Nevertheless, there is a growing body of data that demonstrate acceptable safety and efficacy for the off-label use of current TAVI devices for the treatment of severe AR. Given the dearth of treatment options for inoperable patients with severe AR, available TAVI devices should be considered for this patient population.

中文翻译:

要点:自体主动脉瓣关闭不全患者可采用经导管主动脉瓣植入术治疗

在美国,大约 2% 的 70 至 83 岁的人患有中度或重度主动脉瓣返流 (AR)。如果不及时治疗,这种疾病是进行性和致命的;然而,高达 8% 的符合手术干预标准的 AR 患者未接受治疗。因此,迫切需要解决数千名满足主动脉瓣置换术 I 类指征但仍未接受手术的 AR 患者缺乏治疗选择的问题。经导管主动脉瓣植入术 (TAVI) 的出现显着改变了瓣膜性心脏病的治疗范式,现在已成为严重主动脉瓣狭窄患者行之有效的治疗选择。在研究专用于治疗 AR 的经导管设备时,它们目前还没有商用。尽管如此,越来越多的数据表明,目前 TAVI 设备的标签外使用治疗严重 AR 的安全性和有效性是可接受的。鉴于无法手术的重度 AR 患者缺乏治疗选择,应考虑针对该患者群体使用可用的 TAVI 设备。
更新日期:2021-11-25
down
wechat
bug